Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-11-15
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as pixantrone dimaleate, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving pixantrone dimaleate in different ways may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying how well pixantrone dimaleate works in
treating patients with HER2-negative metastatic breast cancer.